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Abstract 
Objective: To report the progress of the OMERACT Polymyalgia Rheumatica (PMR) Working Group in selecting 
candidate instruments for a core outcome measurement set.  
Methods: A systematic literature review identified outcomes measured and instruments used in PMR studies, and a 
respondent survey and raw data analysis assessed their domain match and feasibility.  
Results: Candidate instruments were identified for pain (VAS/NRS), stiffness (VAS/NRS and duration) and physical 
function (HAQ-DI/MHAQ). Domain match and feasibility assessments were favourable, however validation in PMR 
was lacking.   
Conclusion: Further assessment of candidate instruments is required prior to recommending a PMR core outcome 
measurement set. 
 
Polymyalgia rheumatica (PMR) is an inflammatory disease characterised by sub-acute onset pain and stiffness in the 
shoulders and hips. Oral glucocorticoids represent the mainstay of treatment and whilst cessation of therapy is the 
ultimate goal, up to 50% of PMR patients continue to require prednisolone 2-3 years after diagnosis.(1) It is unclear 
what starting dose or tapering schedule achieves the best outcome, nor what benefit may be offered by putative 
glucocorticoid-sparing agents. Significant morbidity from glucocorticoid-induced complications is recognised and 
likely surpasses that seen in comparable rheumatic conditions.(2)     
 
There is currently no agreed core outcome measurement set for PMR clinical trials. A lack of consistency in definitions 
for domains or instruments used to assess patients with PMR is characteristic of the existing literature.(3) A core 
outcome measurement set for universal use in studies of PMR would improve the quality of future research.        
 
In 2016, OMERACT (Outcome Measures in Rheumatology) endorsed a core domain set for PMR. The inner core of 
the “onion”, signifying items to be measured in all PMR clinical trials, comprised four domains: pain, stiffness, physical 
function and systemic inflammation.(4) Here we report the progress of the PMR Working Group in identifying and 
evaluating suitable instruments mapping to these core domains. This work includes an updated systematic literature 
review, online respondent survey and raw data analysis evaluating the domain match and feasibility of selected 
instruments in line with the first two signalling questions of the OMERACT Filter 2.1: Instrument Selection 
Algorithm.(5-7) The proceedings of the OMERACT 2018 PMR Special Interest Group (SIG) are also detailed, in 
particular the major points discussed, and consensus reached regarding which candidate instruments should continue 
through the Filter.  
 
Systematic literature review  
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To obtain all published articles reporting outcome measures mapping to the OMERACT endorsed PMR core domain 
set, five databases [MEDLINE, CINAHL, Embase, Web of Science, Cochrane Library] were searched from inception 
to 30/9/2017. This yielded 16222 references, which was reduced to 90 full-text studies following removal of duplicates 
and screening abstracts. Forty-six studies were included in the review. Risk of bias was assessed using a modified 
Quality in Prognosis Studies (QUIPS) tool.(8) The systematic review protocol was registered with PROSPERO – 
CRD42017080058.  
   
Two/ten randomised controlled trials and 12/23 prospective cohort studies measured outcomes in each of the four core 
domains. The most commonly assessed domain was systemic inflammation (43/46 studies), usually by erythrocyte 
sedimentation rate (ESR) and/or C-reactive protein (CRP). Pain was measured in 32/46 studies, most often using a visual 
analogue scale (VAS). Stiffness was measured in 28/46 studies, typically as duration of morning stiffness. Physical 
function was assessed in 22/46 of studies, most frequently using the elevation of upper limb (EUL) score as part of the 
PMR-AS(9), or the health assessment questionnaire (HAQ). There was no association between higher-quality clinical 
research trials (assessed by QUIPS tool) and the number of outcomes measured from the core domain set.   
 
Online respondent survey 
The patient perspective on candidate instruments for pain (VAS/numeric rating scale [NRS]), stiffness (VAS/NRS, and 
duration of morning stiffness), physical function (health assessment questionnaire-disability index [HAQ-DI]/modified 
health assessment questionnaire [MHAQ]) and systemic inflammation (ESR/CRP) was evaluated using a web-based 
survey. Google Docs links were created for each instrument and included in the Newswire newsletter of the charity 
PMRGCAuk that is distributed to 1800 readers and the Health Unlocked web forum comprising 6986 members, yielding 
between 28 and 73 responses for each of the instruments examined. Patients were asked a series of questions addressing 
face validity and feasibility that had been developed by consensus of the PMR Working Group. Ethical approval was 
received from the University of East Anglia Research Ethics Committee (2017/18 – 81) and all respondents provided 
written informed consent to publish the results prior to survey completion.   
 
Participants from three continents (Europe, North America, Australia/New Zealand) contributed 51 responses for pain 
VAS/NRS, 51 for stiffness VAS/NRS, 51 for duration of morning stiffness, 73 for HAQ-DI, 28 for MHAQ and 62 for 
ESR/CRP. Disease duration ranged from new diagnosis to 17 years; current prednisolone dose was 0-50mg daily. Most 
respondents agreed candidate instruments were both a suitable match for the target domain and feasible to complete: 
approval for pain VAS was 68.6%/NRS 60.8%; stiffness VAS 62.8%/NRS 58.8%; duration of morning stiffness 58.8%; 
HAQ-DI 70%; MHAQ 53.6%; and ESR/CRP 54.8%. The free text responses further contextualised the numerical scores 
and will be the subject of a separate publication arising from this work.        
 
Raw data analysis  
Two prospective observational cohort studies contributed raw data to further assess the domain match and feasibility of 
candidate instruments for pain, stiffness and physical function: the Melbourne Predictors of Relapse in PMR (MPR-
PMR) study; and The PMR Cohort.(10) Specifics pertaining to each of these studies’ designs and baseline patient 
demographics are outlined in Table 1. Ethical approval was received from the Austin Health Research Ethics Committee 
for the MPR-PMR study (HREC/14/Austin/158) and the Staffordshire Research Ethics Committee for The PMR Cohort 
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(12/WM/0021v), with written informed consent including publication of results provided by all participants in both 
instances prior to study enrolment.       
 
Statistical analysis was conducted using Stata.(11, 12) A data completion rate >80% was ensured for each instrument, 
prior to generating a frequency distribution histogram. The proportion (percentage) of participants with the lowest 
(“floor”) and highest (“ceiling”) values was recorded, and the normality of each distribution assessed (based upon the 
coefficient of skewness where 0 = normal and -0.5 to 0.5 is approximately symmetric). 
 
The data completion rate (≥96.3%) and time taken was deemed acceptable for all of the candidate instruments examined. 
Pain VAS/NRS and stiffness NRS were both associated with >15% of respondents scoring the highest possible value 
(VAS/NRS = 10) at baseline, and the lowest value (VAS/NRS = 0) at multiple timepoints during treatment and follow-
up. Both versions of the HAQ, but especially the MHAQ, were similarly characterized by floor effects (lowest value = 
0) throughout but did not show the same ceiling problems (highest value = 3). The floor and ceiling patterns observed 
appeared consistent with the expected clinical course for patients with newly-diagnosed PMR.   
 
At baseline in both studies, pain levels were at the higher end of the scale (VAS/NRS) then appropriately trended to 
lower values following treatment (Figure 1). Whilst the MPR-PMR study measured duration of morning stiffness, as 
compared with stiffness NRS in The PMR Cohort, the pattern of distribution was similar for both instruments and 
mirrored that seen for pain VAS/NRS. MHAQ results at baseline in The PMR Cohort were typically lower than those 
recorded using HAQ-DI, which might be explained by the shorter format of this instrument. During follow-up, no major 
differences were noted in the performance of the HAQ-DI compared with MHAQ (Figure 2).                  
 
Summary of the OMERACT 2018 PMR SIG 
Participants including clinicians, researchers and patient partners discussed the results of the three workstreams in detail 
at the OMERACT 2018 PMR SIG. The purpose of the SIG was to establish whether instruments mapping to the four 
core domains had satisfied tests for domain match and feasibility, and if they should continue through the OMERACT 
2.1 Filter.(5-7)    
 
The interchangeability of VAS and NRS for the measurement of pain, the most suitable instrument to measure stiffness 
(VAS/NRS versus duration of morning stiffness) and the appropriateness of HAQ as a patient-reported outcome measure 
(PROM) across different age groups and in the modern day represented the major points of discussion. Although the 
raw data analysis revealed no major differences in the performance of pain VAS and NRS in the two PMR populations 
studied, no head-to-head comparison was available, and this may require additional study. VAS/NRS and duration of 
morning stiffness were both acknowledged to possess limitations in their respective abilities to measure the patient 
experience of stiffness (particularly when eliciting responses from non-English speaking patients); this issue is common 
to many rheumatic diseases and no better alternative for measuring stiffness in PMR is currently described. Whilst some 
HAQ questions may be less relevant to older persons (eg. “do chores such as vacuuming or yard work?”) or contextually 
out of date (eg. “run errands?”), it is otherwise a well-validated instrument that in other diseases has been shown to be 
responsive to change over time and capable of discriminating between groups of interest. The development of an entirely 
new instrument for the domain of physical function was therefore deemed unnecessary. However, it is recognised that 
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the overall life impact of PMR reaches beyond the four core domains and there remains an unmet need for a disease-
specific PROM for PMR.  
 
Future research agenda 
At the end of the SIG, consensus was reached amongst the participants that candidate instruments for pain (VAS/NRS), 
stiffness (VAS/NRS and duration of morning stiffness) and physical function (HAQ-DI/MHAQ) were either green 
(“good to go”) or amber (“more work needed or a concern, but go”) for domain match and feasibility. Moving forward, 
the PMR Working Group will focus upon appraising the existing evidence for each instrument’s measurement properties 
before addressing any identified gaps by undertaking focused analysis of relevant datasets.  Our objective is to generate 
a PMR core outcome measurement set for future endorsement by OMERACT.      
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